전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,399 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleShanghai Yunying Medical Techno…Phase 1

R130 (Recombinant oncolytic herpes simplex virus type 1, Recombinant oncolytic herpes simplex virus type 1 (R130))

Lung Cancer; Bronchial Cancer · Sarcoma

#Sarcoma#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 21Status Active
CGTLimited DatastaleIntrexon CorporationPhase 1

CD33-CAR-T Cell Infusion (CD33-CAR-T Cell Infusion)

Hematopoietic/Lymphoid Cancer; Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 20Status Discontinued
AntibodyLimited DatastaleJanssen Research & Development,…Phase 2

Cetrelimab (Cetrelimab)

Carcinoma, Non-Small-Cell Lung · Neoplasms

#Neoplasms#Antibody#Phase2#monoclonal-antibody#Carcinoma+2
Trials 20Status Recruiting
CGTLimited DatastaleCelgenePhase 3

JCAR017 (JCAR017)

Lymphoma, Non-Hodgkin · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#CGT#Phase3#cell-gene-therapy#CAR-T+4
Trials 20Status Active
AntibodyLimited DatastaleJanssen Research & Development,…Phase 2

Bermekimab (Bermekimab)

Dermatitis, Atopic · Hidradenitis Suppurativa

#HidradenitisSuppurativa#Antibody#Phase2#monoclonal-antibody#Dermatitis+2
Trials 19Status Discontinued
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 2

CEA-targeted CAR-T cells (CEA-targeted CAR-T cells)

Gastric Cancer; Colon Cancer · CEA

#CEA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 19Status Active
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Targeted CEA CAR-T (Targeted CEA CAR-T)

Advanced Lung Cancer · CEA

#CEA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 19Status Recruiting
AntibodyLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Vibostolimab (Vibostolimab)

Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#monoclonal-antibody#NeoplasmMetastasis+1
Trials 19Status Recruiting
AntibodyLimited DatastaleNeovii BiotechPhase 2

Catumaxomab (Catumaxomab)

Gastric Cancer; Gastric Adenocarcinoma · Gastric Cancer

#GastricCancer#Antibody#Phase2#monoclonal-antibody#GastricAdenocarcinoma+1
Trials 18Status Active
AntibodyLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Favezelimab (Favezelimab)

Neoplasm Metastasis · Neoplasms

#Neoplasms#Antibody#Phase2#monoclonal-antibody#NeoplasmMetastasis+1
Trials 18Status Discontinued
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, Favezelimab/Pembrolizumab)

Neoplasm Metastasis · Neoplasms

#Neoplasms#Antibody#Phase2#monoclonal-antibody#NeoplasmMetastasis+1
Trials 18Status Active
ADCCurated CorestaleMerck Sharp & Dohme LLCPhase 3

Ifinatamab deruxtecan (Ifinatamab deruxtecan)

Recurrent or Metastatic Solid Tumors · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#BioJungboMoa-pick#antibody-drug-conjugate+2
Trials 18Status Recruiting
AntibodyCurated CorestaleRegeneron PharmaceuticalsPhase 3

Odronextamab (Odronextamab)

Relapsed/Refractory Aggressive B-Cell Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+3
Trials 18Status Recruiting
AntibodyLimited DatastaleBristol-Myers SquibbPhase 2

Urelumab (Urelumab)

Pancreatic Cancer · Malignant Tumors

#MalignantTumors#Antibody#Phase2#monoclonal-antibody#PancreaticCancer+1
Trials 18Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Her2OverexpressingHigh-RiskNon-M+1
Trials 17Status Active
ADCLimited DatastaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Tislelizumab)

Breast Cancer; Neoadjuvant Therapy · Breast Cancer

#BreastCancer#ADC#Approved#antibody-drug-conjugate#NeoadjuvantTherapy+1
Trials 17Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Toripalimab)

Paget Disease, Extramammary; Scrotum Disease · Paget Disease, Extramammary

#PagetDiseaseExtramammary#ADC#Phase2#antibody-drug-conjugate#PagetDisease+3
Trials 17Status Recruiting
CGTLimited DatastaleFate TherapeuticsPreclinical

Genetically engineered NK cells (Genetically engineered NK cells)

Hematological Malignancy · Hematological Malignancy

#HematologicalMalignancy#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 17Status Discontinued
ADCLimited DatastaleDaiichi SankyoPhase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, T-Dxd + Pertuzumab)

HER2 + Breast Cancer · HER2

#HER2#ADC#Phase3#antibody-drug-conjugate#HER2+BreastCancer+1
Trials 17Status Recruiting
AntibodyLimited DatastaleKite, A Gilead CompanyPhase 1

Utomilumab (Utomilumab)

Relapsed/Refractory Large B-cell Lymphoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#Relapsed+2
Trials 17Status Active

21 / 120 pages

← PreviousNext →